ArticleFrontiers in behavioral neuroscience2015
Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down Syndrome: Implications of a 6-month Observational Study.
Article in Frontiers in behavioral neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review.Journal of neurodevelopmental disorders · 2019Pooled it
- A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAJournal of neurodevelopmental disorders · 2022Trial
- One-year effects of bifocal and unifocal glasses on executive functions in children with Down syndrome in a randomized controlled trial.Scientific reports · 2021Trial
- Radiological Screening of Atlantoaxial Instability in Children with Trisomy 21: A Systematic Review and Evidence-Based Recommendations.Children (Basel, Switzerland) · 2025Review
- Transcranial photobiomodulation for neurodevelopmental disorders: a narrative review.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Review
- Neurodevelopmental Disorders Associated with Gut Microbiome Dysbiosis in Children.Children (Basel, Switzerland) · 2024Review
- Implications of Using the BRIEF-Preschool With School-Age Children With Down Syndrome.American journal on intellectual and developmental disabilities · 2024Article
- Combined sensory integration therapy plus neurodevelopmental therapy (NT) versus NT alone for motor and attention in children with Down syndrome: a randomized controlled trial.International journal of developmental disabilities · 2024Article
- BENDI: Improving Cognitive Assessments in Toddlers and Children with Down Syndrome Using Stealth Assessment.Children (Basel, Switzerland) · 2023Article
- Psychometric properties of inhibitory control measures among youth with Down syndrome.Journal of intellectual disability research : JIDR · 2023Article
- Evaluating Processing Speed and Reaction Time Outcome Measures in Children and Adolescents with Down Syndrome.International journal of environmental research and public health · 2023Article
- Cognitive flexibility assessment in youth with Down syndrome: Reliability, practice effects, and validity.Research in developmental disabilities · 2023Article
- ProfilingFrontiers in cellular and infection microbiology · 2023Article
- The Mediatory Role of Executive Functioning on the Association Between Sleep and Both Everyday Memory and ADHD Symptoms in Children and Youth With Down Syndrome.American journal on intellectual and developmental disabilities · 2023Article
- Evaluating Verbal Fluency Outcome Measures in Children With Down Syndrome.American journal on intellectual and developmental disabilities · 2022Article
- Evidence of Energy Metabolism Alterations in Cultured Neonatal Astrocytes Derived from the Ts65Dn Mouse Model of Down Syndrome.Brain sciences · 2022Article
- Evaluating working memory outcome measures for children with Down syndrome.Journal of intellectual disability research : JIDR · 2022Article
- Considerations for measuring individual outcomes across contexts in Down syndrome: Implications for research and clinical trials.International review of research in developmental disabilities · 2022Article
- Short-term memory outcome measures: Psychometric evaluation and performance in youth with Down syndrome.Research in developmental disabilities · 2022Article
- Executive functions and adaptive behaviour in individuals with Down syndrome.Journal of intellectual disability research : JIDR · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior. Previous pharmacological studies in this population have been limited by a lack of appropriate endpoints that accurately measured change in cognitive and functional abilities. Therefore, the current longitudinal observational study assessed the suitability and reliability of existing cognitive scales to determine which tools would be the most effective in future interventional clinical studies. Subtests of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Cambridge Neuropsychological Test Automated Battery (CANTAB), and Clinical Evaluation of Language Fundamentals-Preschool-2 (CELF-P-2), and the Observer Memory Questionnaire-Parent Form (OMQ-PF), Behavior Rating Inventory of Executive Function®-Preschool Version (BRIEF-P) and Leiter International Performance Scale-Revised were assessed. The results reported here have contributed to the optimization of trial design and endpoint selection for the Phase 2 study of a new selective negative allosteric modulator of the GABAA receptor α5-subtype (Basmisanil), and can be applied to other studies in the DS population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.